Headache

Headache

The unmet needs of migraine patients 1:25
The unmet needs of migraine patients
Jessica Ailani
Long-term intermittent use of ubrogepant to treat acute migraines 5:26
Long-term intermittent use of ubrogepant to treat acute migraines
Jessica Ailani
Therapeutic landscape for cluster headache 11:31
Therapeutic landscape for cluster headache
Stewart Tepper
Challenges in migraine management 2:09
Challenges in migraine management
Uwe Reuter
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic 20:54
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic
Stewart Tepper
BKCa channels: potential novel anti-migraine target 4:14
BKCa channels: potential novel anti-migraine target
Messoud Ashina
Benefit of migraine prevention with erenumab 19:11
Benefit of migraine prevention with erenumab
Stewart Tepper
The evolving landscape of migraine treatment and prevention 3:42
The evolving landscape of migraine treatment and prevention
Uwe Reuter
PROMISE-1: eptinezumab in episodic migraine 2:44
PROMISE-1: eptinezumab in episodic migraine
Messoud Ashina
Understanding migraines better with AI 0:58
Understanding migraines better with AI
Dagny Holle-Lee
Fremanezumab in patients with chronic or episodic migraine 2:52
Fremanezumab in patients with chronic or episodic migraine
Uwe Reuter
CONQUER: galcanezumab in treatment-resistant migraine 9:29
CONQUER: galcanezumab in treatment-resistant migraine
Stewart Tepper
HER-MES study: erenumab versus topiramate in episodic migraine 2:30
HER-MES study: erenumab versus topiramate in episodic migraine
Uwe Reuter
Migraine: CGRP mAbs efficacy measured over time 1:30
Migraine: CGRP mAbs efficacy measured over time
Dagny Holle-Lee
The evolving migraine prevention landscape: EAN 2020 highlights 3:29
The evolving migraine prevention landscape: EAN 2020 highlights
Messoud Ashina
LIBERTY trial: erenumab in episodic migraine patients with prior preventive treatment failures 2:33
LIBERTY trial: erenumab in episodic migraine patients with prior preventive treatment failures
Uwe Reuter
The content of VJNeurology is intended for healthcare professionals